INVENTISBIO CO., LIMITED

Highlights InventisBio Co., Limited

Equities

688382

CNE100005Q22

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
8.71 ^CNY	+0.46%		+2.11%	-42.47%

Apr. 29	InventisBio Co., Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 11	Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

InventisBio Co., Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	Apr. 10	MT
InventisBio Co., Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 05	CI
InventisBio Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
InventisBio, Beida Pharmaceutical Get Registration Certification for Befortinib Mesylate Capsules	23-10-13	MT
InventisBio Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
Sino Biopharm Unit Gets Exclusive License to Develop Inventisbio's Cancer Drug	23-08-03	MT
Chia-Tai Tianqing Pharmaceutical Group Co., Ltd Enters into Exclusive License and Cooperation Agreement with Inventisbio Co., Ltd	23-08-03	CI
InventisBio Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
InventisBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
InventisBio Co., Ltd. has completed an IPO in the amount of CNY 2.0838 billion.	22-07-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer